## FILING BY "EXPRESS MAIL" UNDER 37 PROPERC'S PC

EV5246/498245 Express Mail Label Number

Other items or information: Unexecuted Declaration

Date of Deposit

Form PTO-1390-MOD U. S. Department of Commerce Patent and Trademark Office ATTORNEY'S DOCKET NUMBER (REV 10-96) ON/4-32671A U.S. APPLICATION NO. (If known, see 37 CFR 1.5) TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) **CONCERNING A FILING UNDER 35 U.S.C. 371** INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATE PRIORITY DATE CLAIMED PCT/EP03/10171 12 September 2003 (12.09.03) 13 September 2002 (13.09.02) TITLE OF INVENTION A NEW PROCESS FOR THE PREPARATION OF EPOTHILONE DERIVATIVES, NEW EPOTHILONE DERIVATIVES AS WELL AS NEW INTERMEDIATE PRODUCTS FOR THE PROCESS AND THE METHODS OF PREPARING SAME APPLICANT(S) FOR DO/EO/US KOCH ET AL.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information: This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 2. 3. This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5.  $\boxtimes$ A copy of the International Application as filed (35 U.S.C. 371(c)(2)) is transmitted herewith (required only if not transmitted by the International Bureau). has been transmitted by the International Bureau. (See Form PCT/IB/308) c. is not required, as the application was filed in the United States Receiving Office (RO/US). A translation of the International Application into English (35 U.S.C. 371(c)(2)). Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C.371(c)(3)). a. 

are transmitted herewith (required only if not transmitted by the International Bureau). b. have been transmitted by the International Bureau. have not been made; however, the time limit for making such amendments has NOT expired. have not been made and will not be made. A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)). An executed Declaration and Power of Attorney (original or copy) (35 U.S.C. 371(c)(4)). A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). Items 11. to 16. below concern document(s) or information included. 11. An Information Disclosure Statement under 37 CFR 1.97 and 1.98. 12. An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. A FIRST preliminary amendment. A SECOND or SUBSEQUENT preliminary amendment. 14. An Application Data Sheet under 37 CFR 1.76. 15. A substitute specification. A change of power of attorney and/or address letter. 17. A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825. 18. A second copy of the published International Application under 35 U.S.C. 154(d)(4). 19. A second copy of the English language translation of the International application under 35 U.S.C. 154(d)(4).

U.S. APPLICATION NO	T koon.	7526	28 PC	NATIONAL APPLICATION NO.  (F/EP03/10171			ON/4-326		MBER	
The following fees are submitted:								CALCULATIONS PTO USE		
								ONLY		
21. 🛛 Basic national fee										
22. Examination Fee										
If International preliminary examination report was prepared by USPTO and all claims satisfy provisions of PCT Article 33(1)-(4)										
23. Search fee										
☐ If Search fee (37 CFR 1.445(a)(2)) has been paid on the international										
application to the USPTO as an International Searching Authority \$  If International Search Report was prepared and provided to the Office \$										
All other situations. \$500										
TOTAL OF 21, 22 AND 23 =								s	1,000	
Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing										
program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.										
Total Sheets	Sheets Extra sheets Number of each additional 50 or fraction RATE						ΤE			
59 - 100 =	0	/50 =	thereof (round	d <b>up</b> to a whole number	<del>)</del>   x	\$	250	\$		
			l <u> </u>		***************************************					
Surcharge of \$130 for furnishing the oath of declaration later than 30 months from the earliest claimed priority date (37 CFR 1.492(e)).								\$		
CLAIMS NUMBER FILED NUMBER EXTRA RATE										
Total claims		34	- 20 =	14	X	\$	50	\$	700	
Independent claims 27			- 3 =	24	X   +	\$ \$	200 360	\$	4,800	
MULTIPLE DEPENDENT CLAIM(S) (if applicable) + \$ 360  TOTAL OF ABOVE CALCULATIONS =								\$	6,500	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be								Ť		
filed (Note 37 CFR 1.9, 1.27, 1.28).								\$	6,500	
SUBTOTAL =  Processing fee of \$130 for furnishing the English translation later than  30 months from the								φ	0,500	
earliest claimed priority date (37 CFR 1.492(f)).								\$		
TOTAL NATIONAL FEE =								\$	6,500	
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40 per property +								\$		
TOTAL FEES ENCLOSED =								\$	6,500	
									ount to	\$
									funded harged	\$
a. A chec	k in the	amount of \$		to cover the above f	ees is encl	losed.			gov	
b.   Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$6,500 to cover the above fees. A duplicate copy of this form is enclosed.										
c.   The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 19-0134 in the name of Novartis.										
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.										
Send all correspondence to the address associated with Customer No. 001095, which is currently:										
	• •		•	چ	UM	(A)	siend			
Oona A. Jackson / Novartis Attorney for Applicants										
Corpora	Corporate Intellectual Property Reg. No. 48,152									
One Health Plaza, Building 104 (862) 778-7852 East Hanover, NJ 07936-1080										